HOME >> BIOLOGY >> NEWS
Penn researchers determine structure of binding site of colon-cancer drug and its protein target

(Philadelphia, PA) Researchers at the University of Pennsylvania School of Medicine have determined the precise molecular details of how Erbitux, a recently approved colorectal cancer drug, binds to its target on cancer cells. Knowing this chemical configuration will lead to better drug design for this family of cancer medications.

Colorectal cancer is one of the most frequently diagnosed cancers in men and women, as well as the second-leading cause of cancer-related death, according to the Centers for Disease Control and Prevention. Erbitux works by binding to a protein on the surface of cancer cells, thereby halting excessive cell growth that leads to tumors. Kate Ferguson, PhD, Assistant Professor of Physiology, and colleagues, describe their findings in the April cover article of Cancer Cell.

"By having determined the structure of Erbitux bound to its cellular target receptor, we get new insight into how the drug blocks the receptor's cell growth-promoting activities, and can use this to guide future drug design," says Ferguson.

As is characteristic of many epithelial cancers such as cancers of the head and neck, breast, ovary, lung, and pancreas the surface of cancer cells possess abnormally high levels of epidermal growth factor receptor (EGFR), the protein that interacts with Erbitux. These receptors are made up of three parts: one outside the cell; another passing through the cell membrane; and the third inside the cell. In a cancer cell, an extracellular hormone binds to the outer piece of EGFR, and causes the inside part to kick off a series of reactions that signal the cancerous cell to replicate and divide.

Ferguson and colleagues determined that Erbitux works to halt cell proliferation by blocking EGFR's molecular doorway, disallowing hormones to bind and signal tumor growth. X-ray crystallography provided a snapshot of the interaction between Erbitux and the extracellular component of the cancer cell's receptors. '"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
18-Apr-2005


Page: 1 2

Related biology news :

1. Innovative tagging technique may help researchers better protect fish stocks
2. Penn researchers discover how key protein stops inflammation
3. ASU researchers partner with UOP to make biofuel for military jets a reality
4. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
5. Penn researchers discover pathway that eliminates genetic defects in red blood cells
6. U-M researchers find family of on switches that cause prostate cancer
7. 2007 EURYI: 20 young researchers to receive Nobel Prize-sized awards for breakthrough ideas
8. Pets could be source of multiresistant bacteria infections in humans, MU researchers investigate
9. MGH researchers confirm that bone marrow restores fertility in female mice
10. Smithsonians National Zoo researchers use electronic eggs to help save threatened species
11. U-M researchers identify gene involved in breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/7/2017)... February 7, 2017 Ipsidy Inc. ... Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a provider ... processing services, is pleased to announce the following changes ... Effective January 31, 2017, Philip D. Beck ... CEO and President.  An experienced payment industry professional and ...
(Date:2/3/2017)... -- Texas Biomedical Research Institute announced that its Board of Trustees ... the Institute,s new President and CEO. Dr. Schlesinger will take ... is currently the Chair of the Department of Microbial Infection ... Biology at Ohio State University. "We are delighted ... of Texas Biomed," said Dr. James O. Rubin , ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill ... a strange place for a head lice treatment salon to ... between a Tuscan restaurant and a French bistro on E ... perfect. "We aren,t just any old lice clinic, we pride ... feel comfortable, and release some of the stigma associated with ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... published evaluation of multiple immunoassay-based threat detection technologies by researchers from the ... CANARY® biosensor threat detection technology was found to have the best level ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The Greater ... a new partnership with Compass Research . GGI's mission is to advance global ... to a child in need in honor of each clinical trial volunteer. The vision ...
(Date:2/23/2017)... SAN DIEGO and SAN FRANCISCO ... , a privately-held regenerative medicine company, and Beyond Type ... living with type 1 diabetes, today announced a grant ... develop a functional cure for type 1 and other ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
Breaking Biology Technology:
Cached News: